FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing high response rates.
Nuvation Bio’s Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval
Where Today's News Shapes Tomorrow
